Rhode Island Chronicle

Short Bowel Syndrome Pipeline | Companies – VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and Others

 Breaking News
  • No posts were found

Short Bowel Syndrome Pipeline | Companies – VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and Others

June 01
08:12 2023
Short Bowel Syndrome Pipeline | Companies - VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and Others

DelveInsight’s, “Short Bowel Syndrome Pipeline Insight 2023” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Short Bowel Syndrome pipeline landscape. It covers the Short Bowel Syndrome pipeline drug profiles, including Short Bowel Syndrome clinical trials and nonclinical stage products. It also covers the Short Bowel Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Short Bowel Syndrome Pipeline treatment landscape of the report, click here @ Short Bowel Syndrome Pipeline Outlook

 

Key Takeaways from the Short Bowel Syndrome Pipeline Report

  • DelveInsight’s Short Bowel Syndrome Pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Short Bowel Syndrome.
  • The leading Short Bowel Syndrome Companies include VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and Others
  • Promising Short Bowel Syndrome Pipeline Therapies include Teduglutide, Apraglutide, Glepaglutide, and others
  • Glepaglutide is developed by Zealand Pharma, which is under Phase III stage of clinical development for the treatment of patients with SBS. The drug received orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of SBS in October 2017. Glepaglutide is a long-acting GLP-2 analog with an effective half-life of ~50 h. The drug is given as once- or twice-weekly dosing via autoinjector. Moreover, the Phase II results showed an increase in intestinal absorption following 3 week administration. The Phase III program will provide up to 4.5 years patient exposure to glepaglutide and clinical evidence for efficacy and safety. The company announced completion of patient enrollment in the pivotal Phase III trial (EASE-SBS 1) of glepaglutide. Furthermore, the full results of the EASE-SBS 1 pivotal Phase III trial are expected in the third quarter of 2022.
  • In Feb2022, the company announced that the first patient has been dosed in its pivotal Phase III (STARS) trial of Apraglutide in SBS.The pivotal study is expected to be completed by June 2023 and the topline results are expected by end of 2023. The FDAhas granted Orphan Drug designation to Apraglutide an investigational treatment for SBS. Apraglutide is the lead candidate of the VectivBioand the companycompleted the Phase II clinical trial. Apraglutide has successfully completed Phase II studies and is currently being evaluatedin a pivotal Phase III clinical trial. In Phase II, the drug showed an Increase in intestinal absorption after weekly dosing.
  • In April 2021, 9 Meters Biopharma entered into a collaboration with the Duke Clinical Research Institute (DCRI) to support the clinical development of 9 Meters’ candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in Phase 2 development for short bowel syndrome (SBS).

 

For further information, refer to the detailed Short Bowel Syndrome Unmet Needs, Short Bowel Syndrome Market Drivers, and Short Bowel Syndrome Market Barriers, click here for Short Bowel Syndrome Ongoing Clinical Trial Analysis

 

Short Bowel Syndrome Overview

Short bowel syndrome (SBS) in adults is defined as less than 180 to 200 centimeters of remaining small bowel (normal length 275 to 850 cm) leading to the need for nutritional and fluid supplements. Short bowel syndrome may be classified as a cause or subcategory of intestinal failure.

 

Short Bowel Syndrome Emerging Drugs Profile

 

  • Glepaglutide: Zealand Pharma

Glepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome (SBS). Glepaglutide is being developed as a liquid product in an autoinjector designed for subcutaneous administration, aimed to reduce, or eliminate, the need for parenteral support in people living with SBS. Currently the product is in Phase III stage of development for the treatment of Short Bowel Syndrome.

 

Request a sample and discover the recent advances in Short Bowel Syndrome Ongoing Clinical Trial Analysis and Medications, click here @ Short Bowel Syndrome Treatment Landscape

 

Short Bowel Syndrome Pipeline Therapeutics Assessment

There are approx. 18+ Short Bowel Syndrome companies are developing Short Bowel Syndrome therapies. The Short Bowel Syndrome companies which have their Short Bowel Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Zealand Pharma.

 

Dive deep into rich insights for drugs for Short Bowel Syndrome Market Drivers and Short Bowel Syndrome Market Barriers, click here @ Short Bowel Syndrome Unmet Needs and Analyst Views

 

Scope of the Short Bowel Syndrome Pipeline Report

  • Coverage- Global
  • Short Bowel Syndrome Companies- VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and Others
  • Short Bowel Syndrome Pipeline Therapies- Teduglutide, Apraglutide, Glepaglutide, and others.
  • Short Bowel Syndrome Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Short Bowel Syndrome Mergers and acquisitions, Short Bowel Syndrome Licensing Activities @ Short Bowel Syndrome Emerging Drugs, and Recent Trends

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Short Bowel Syndrome: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Short Bowel Syndrome – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Glepaglutide: Zealand Pharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. HM 15912: Hanmi Pharmaceutical
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase II)
  14. Vurolenatide: 9 Meters Biopharma
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. SEFA-6179: NorthSea Therapeutics
  18. Drug profiles in the detailed report…..
  19. Preclinical and Discovery Stage Products
  20. GLP2-ELP: PhaseBio Pharmaceuticals
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Short Bowel Syndrome Key Companies
  24. Short Bowel Syndrome Key Products
  25. Short Bowel Syndrome- Unmet Needs
  26. Short Bowel Syndrome- Market Drivers and Barriers
  27. Short Bowel Syndrome- Future Perspectives and Conclusion
  28. Short Bowel Syndrome Analyst Views
  29. Short Bowel Syndrome Key Companies
  30. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Categories